The above article examines whether TAV in TAV is a good option for patients going forward.
"long-term patient management is now at the forefront of physicians’ minds when they treat patients with severe symptomatic aortic stenosis"
"there is a growing awareness that younger, lower-risk patients with longer life expectancies will live beyond the valve’s life span, making TAV-in-TAV procedures more common going forward"
For AVR holders, the obvious point to make is the best option for patients would be if they did not need to replace it in the first place
Good luck all.
AVR Price at posting:
$27.45 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)